Dr. John Faessel's  Instablog

Dr. John Faessel
Send Message
Dr. John L. Faessel is a seasoned and respected Wall Street professional with industry-wide recognition for expertise in market strategy and analysis. He is widely recognized for his insights in public companies. For over 20-years Dr. Faessel’s ON THE MARKET reports have been widely distributed... More
  • STAR SCIENTIFIC (STSI) > Anatabine 101 & The Trend Is Your Friend. 5 comments
    Aug 31, 2012 3:43 PM | about stocks: RCPI


    Dr. John L. Faessel


    Commentary and Insights


    Anatabine 101


    Where we've been & where we're going: Tobacco ― Anatabine ― Anatabloc™

    There is a whole new audience out there that's just being introduced to Star's Anatabloc™ and I get contacted daily by those who wish to understand what this compound is, where it came from and where it's going? So at times, and this is one of them, we need to see where we've been to know better where we're going, such is the case for the tobacco-based alkaloid anatabine that evolved into Anatabloc™. The maxim, "The trend is your friend" rings true.

    The narrative begins with tobacco; and some observations that were made near a decade ago by Johns Hopkins researchers who were studying thyroid disease in flight attendants were they found a marked reduction of the illness. Because of the confined space in airliners the exposure to tobacco smoke offered them a rare picture to study. While the Johns Hopkins researchers didn't pursue further tobacco studies because of the onus of its ills they knew that there was something "good" in tobacco.

    Back in 2007, researchers at the Harvard School of Public Health found that after analyzing 11 separate studies, smokers were found to be 73% less likely to suffer from Parkinson's disease than those who didn't smoke. The study went on to state the obvious-namely that "further research could determine which chemicals are responsible for bolstering the brain against the illness." Importantly, the study also found that more years of smoking were associated with less risk.

    Parallel with the above mentioned studies Star Scientific had been doing some tobacco research in search of, and finally finding the cancer-causing agents in tobacco. This is the basis for the current lawsuit against Reynolds Tobacco (NYSE:RAI) that's currently before the US Supreme Court and other courts. It's been more than 10 years slog for Star to get to this point.

    Next in the timeline, Stars CEO Jonnie Williams determined, in what may be a breakthrough of profound implications for mankind, that one of the 4000 chemicals in tobacco /nicotine, namely Anatabine, reduced the urge to smoke. He came to this conclusion because of the profound addictive qualities of nicotine, determining that something else in tobacco smoke, more than the nicotine was responsible for its addictive qualities. He / Star began to market the over-the-counter CigRx as an aid to help quell the urge to smoke. What Star found was that the anatabine-based compound had many/now hundreds, of other beneficial effects on those that took CigRx. Anatabloc™ was born...

    This information that came out of the blue, was quite surprising to those at Star who were tracking those folks who took the CigRx compound. Harvard also did some extensive mouse studies re Anatabine and corroborated 'it's' effects. Subsequent research followed and it was found that anatabine had powerful anti-inflammatory effects. An important part of this story line occurs when Jonnie Williams wife is facing serious thyroid surgery because of his advanced thyroiditis; Williams then suggests to the Johns Hopkins surgeons that he would have his wife take some of the companies, (now determined to be anti-inflammatory) anatabine compound. Amazingly, the thyroiditis was healed. The "Ah Ha!" moment was at hand. Johns Hopkins then became very interested and they began their thyroid research.

    Johns Hopkins University School of Medicine is soon to release the results of a thyroid study performed in nine clinical sites in Michigan, Texas, New Jersey, Illinois, and Florida, referred to as the Anatabloc Supplementation Autoimmune Prevention thyroid study. It is estimated by analyst Otis Bradley (Gilford Securities) that, "treatment of thyroid diseases using Star's anatabine technology could cause sales of Star's Anatabloc™ anti-inflammatory tablet (now on the market over-the-counter) to skyrocket from virtually nothing today to an annual run-rate over $400 million (with profit of $200 million or $1.00 per share) in 2013."

    In the United States alone over 70 million thyroid prescriptions are written (the 4th most prescribed for the disease) at a value of about $2 billion.

    Recall that at a meeting at the Roskamp Institute I attended in June 2011, Dr. Paul Ladenson, Director of the Division of Endocrinology at Johns Hopkins stated that, "aside from RCP-006 (anatabine - now Star's Anatabloc™) there is no known compound that stops thyroiditis."

    Florida's Roskamp Institute also became interested in the compounds anti-inflammatory effects and they have accomplished breakthrough research quantifying anatabine (RCP-006) effects in several studies on mice and human blood. The results showed that dramatically reduces inflammation/ (RCP-006) - is more than four (4) times more effective than either Celebrex or Voltarol in reducing inflammation and was shown to be more than three (3) times more effective than Lipitor in reducing inflammation in whole human blood. These are drugs that require prescriptions from a physician and their sales are in the mega-billions: Lipitor sales in 2010 alone were $10.7 billion.

    Key Peer review validating the Roskamp research then followed in the European Journal of Pharmacology under the Molecular and Cellular Pharmacology heading, titled Anatabine lowers Alzheimer's Aβ production in vitro and in vivo.

    Importantly Roskamp's research was also validated by a study released by Vanderbilt University Medical Center by Dr. Paul Newhouse that was reported in the January 10 issue of Neurology. It was the first reference in the medical literature re "improvements" of cognitive impairment in human subjects with mild cognitive impairment [MCI] using nicotine. Participants also reported "feeling sharper while on the (nicotine) patch".

    Under the Vanderbilt Conclusions:

    1. "This study demonstrated that transdermal nicotine can be safely administered to nonsmoking subjects with mild cognitive impairment [MCI] over 6-months with improvement in primary and secondary cognitive measures of attention, memory, and mental processing"

    2. "The primary cognitive outcome measure [CPT] showed a significant nicotine-induced improvement."

    3. "The secondary outcome measures showed significant nicotine-associated improvements in attention, memory, and psychomotor speed, and improvements were seen in patient/informant ratings of cognitive impairment."

    4. "We conclude that this initial study provides evidence for nicotine-induced cognitive improvement in subjects with mild cognitive impairment [MCI]"

    It follows of course, that Anatabine / now Stars Anatabloc™ originating from nicotine could well be in the "element" in nicotine responsible for the above Vanderbilt conclusions.

    Michael Mullan (MD, Ph.D.) Roskamp's Director of Research and CEO commented on the Vanderbilt study:

    · Dr. Newhouse suggests that Nicotine patches may be very beneficial in individuals with mild cognitive impairment [MCI].

    · "Mild cognitive impairment [MCI] is frequently regarded as a precursor to Alzheimer's disease"

    · According to studies at Harvard University. "Anatabine is also a tobacco leaf-derived product, but, has no known carcinogen effects, nor does it seem to have any addictive potential."

    · This recent study, using Nicotine patches for six months, has shown that individuals under the influence of Nicotine showed a 46% improvement in their "long-term memory"

    · In addition Anatabine has been shown by scientists at the Roskamp Institute to be beneficial in mitigating against memory decline in animal models of Alzheimer's disease.

    · Studies with Anatabine show that amyloid protein, the causative agent in Alzheimer's disease, is reduced in animal models of the disease and that this reduction parallels the improvement in memory seen with treatment with Anatabine.

    · Dr. Mullan also commented (1/11/2012) in a press release from Star Scientific Inc., "Anatabine may have several advantages over nicotine in the support of memory with aging. For instance, anatabine seems to have a longer half-life in the blood, which necessitates less frequent dosing, and has shown no abuse potential in animal screening. In addition, anatabine is able to lower amyloid levels in animal models of Alzheimer's disease which become abnormally high as the disease progresses." Dr. Mullan also commented that the Roskamp Institute is actively pursuing the use of anatabine as a support for memory loss, and will be initiating human studies to explore further this potential role for anatabine."

    Roskamp has just recently undertaken human Alzheimer's studies.

    · Obviously, from a commercial point of view there is no patent position on nicotine, and no one could get one - so the Anatabine [Anatabloc™] alternative is attractive.

    · We also know that the Anatabine stays over twice as long in the body as a cigarette delivered dose of nicotine; 8-hours vs. 4-hours.

    · It therefore appears that all the beneficial effects that the nicotine patch accomplishes for subjects with mild cognitive impairment is achieved by Anatabine without the deleterious effects of addiction, potential toxicity and the numerous tobacco related medical horrors. Anatabine can also be dosed in a more effective regimen while also benefiting from the increase in half-life.

    · Taken as a whole I believe this Vanderbilt study is of huge consequence in the ever improving storyline of Anatabine [Anatabloc™] in reference to Alzheimer's disease. As readers know the Roskamp Institute is well into extensive studies and trials of patients that demonstrate mild cognitive impairment, dementia and Alzheimer symptoms. Again, this study adds credence to the evolution of a possible successful treatment modality.

    The market for Anatabloc™ as a reducer of low grade inflammations is of staggering proportions: the product targets chronic inflammation known to be present in a number of coronary and vascular diseases, cancers and in auto-immune diseases such as thyroid disease, diabetes, asthma, Crohn's, Irritable Bowel Syndrome, Alzheimer's, Parkinson's and arthritis, besides numerous other conditions and bodily woes ― and that includes ageing.

    An excerpt from the Wikipedia epidemiology page on cardiovascular disease encapsulates much of the Roskamp research thesis: "A fairly recent emphasis is on the link between low-grade inflammation that hallmarks atherosclerosis and its possible interventions. C-reactive protein [CRP] is a common inflammatory marker that has been found to be present in increased levels in patients at risk for cardiovascular disease.[22] Also osteoprotegerin which involved with regulation of a key inflammatory transcription factor called NF-κB has been found to be a risk factor of cardiovascular disease and mortality."

    Links to the Roskamp research:




    Originally, Anatabloc™ was sold only online through the Star Scientific website and then from the Amazon and Facebook pages. More recently, General Nutrition centers (NYSE:GNC) NYSE also began selling Anatabloc™ online, and from what we hear about the brisk sales (even leading to back orders) there are rumors that it won't be long before the product is carried in many more of (GNC)'s over 7,600 locations in 53 countries.

    In January Star announced that it had completed a successful human clinical trial showing that Anatabloc™ lowers chronic inflammation as measured by C-reactive protein [CRP] levels in human subjects' blood. (A Google search of CRP yielded 24,000,000 results.)

    Jonnie Williams, Star Scientific CEO has stated, "Anatabloc™ (anatabine) is a non-prescription anti-inflammatory product that revolutionizes inflammatory control as we know it. The studies that are already public show what the anatabine compound is capable of, and the implications for what this means to millions of individuals are limitless."

    Roskamp Institute directors and biomedical researchers Michael Mullan (MD, Ph.D.) and Fiona Crawford (Ph.D.) were key members of a pioneering team of scientists who more than a decade ago discovered that the onset of Alzheimer's was directly related to the accumulation of a protein called ß-amyloid.

    Roskamp testing shows that when the anatabine compound (now called Anatabloc™) that was developed by Rock Creek, a Star Scientific subsidiary, is applied to cells, ß-amyloid is reduced. The compound also appears to encourage new neuronal cell growth.

    Rock Creek also filed a patent indicating that C-reactive Protein [CRP] markers are lowered when the anabatine compound is applied to cells. The provisional patent application discloses that S-(-)-anatabine positively correlates with reduction of the inflammatory activity that results in elevated blood levels of inflammation markers such as CRP. Notable is that Star's "ambassador" golfer great, tour-pro Fred Couples CRP level has dropped from 6.5 to 0.5 since he began taking Anatabloc™.

    The science risk is now close to nil as there is a mass of confirming data, quotes from prestigious names, research done by influential and potent supporting scientific entities (Johns Hopkins, Harvard, Roskamp) powerful institutions funding the research (Walton Family Foundation and the National Institutes of Health [NIH] for two) and a building avalanche of anecdotal testimonials that in sum make the science a fiat accompli.

    From what I hear the "word" is spreading fast in the domain of many professional sports and I'm sure 'that' will likewise filter into amateur athletics as well. Importantly, numerous and well respected coaches in many athletic disciplines are also spreading the word. Plus super celebrities and mega politicians are also taking the nutritional supplement and I expect to soon see large HMOs recommend Anatabloc™ to their members as well. In addition, the introduction of the Anatabloc™ cream is due to occur shortly and it's supposed to be to be widely marketed. So in sum, a tremendous amount of real progress on many fronts has been accomplished by Star and the wave is still building. More fun awaits... like Al Jolson (arguably in his day - the most popular, most loved, most famous and highest paid entertainer) said, "You ain't seen nothin' yet!"

    Disclosure: I'm an investor in Star Scientific shares and have bought shares on the open market and have no affiliation with the company other than as a shareholder.

    If you missed my previous reports-more specific in detail and scope on each of these themes send a request to: Dr.Faessel@onthemar.com

    The Roskamp Institute website; http://www.rfdn.org/

    To view the new Anatabloc™ website; http://anatabloc.com/

    Disclosure: I am long STSI.

    Additional disclosure: Disclosure: I'm an investor in Star Scientific shares and have bought shares on the open market and have no affiliation with the company other than as a shareholder.

    Stocks: RCPI
Back To Dr. John Faessel's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (5)
Track new comments
  • The_Hammer
    , contributor
    Comments (5114) | Send Message
    Is this not a rehash of stuff you put out in the past?


    I see the stock is breaking down. in the high $3's.


    $550 mil market cap is pricing in some good news already. Maybe if some hotair comes out of this stock maybe worthwhile spec
    31 Aug 2012, 01:54 PM Reply Like
  • silence_twain
    , contributor
    Comments (338) | Send Message
    The Hammer: You seem to be correct in calling this rehash of stuff that has already been talked about. I had dinner tonight with a family member who is a Doctor (graduated University of Chicago Med School) and he found the story that STSI was spinning with regards to Anatabloc to be quite funny. You also make a good point when you cite the market cap and that a lot of growth is already implied by that market cap.
    2 Sep 2012, 09:37 PM Reply Like
  • justhinkin
    , contributor
    Comments (66) | Send Message
    You just love to talk (on and on, all over the place) about things you know nothing about, don't you?


    Having told your knowledge-less tale of Anatabloc to some doctor (so you say) over dinner, there is little doubt he could not come to any fact based conclusion.


    Tell me ... was he laughing at the research by the head of endocrinology at Johns Hopkins, Dr. Ladenson? By Mullan and Crawford at Roskamp Institute? The peer reviewed studies by these folks in mouse models for thyroiditis, Alzheimer's, and M.S.? The Flint MI clinical trials on lowering C-RP in progress? The clinical trials on halting or reducing Hashimoto's thyroiditis by Ladenson in progress? The clinical trials by Mullan for efficacy in mild to moderate Alzheimer's in progress?


    Please ... explain at length just what did he find so funny about these things?


    What ... you forgot to mention them to him (but of course you DO know about them, right?). Now, how or rather why would you forget such things?


    Please go to these same great lengths, say 9 months from now, all over the place, to explain how you could have missed so very much important information about something you seem to have such a keen, yet factually void, interest in. AND ... WHY.


    The one thing that Anatabloc doesn't do for me: vacuous people like you STILL MAKE ME SICK.
    4 Sep 2012, 02:08 AM Reply Like
  • at322
    , contributor
    Comments (2) | Send Message
    I just love how R.J. Reynolds is so bitter about losing a court battle that they will go to great lengths to downplay the importance of Anatabloc. Bottom line: you tried to steal one of the greatest medical breakthroughs in the history of human beings and you lost. I am so glad people continue to bash this stock. I can continually buy it at the $3.00 range when it will be worth 100 times that when the Johns Hopkins study is released. Of course, I do not need to see the study. My grandfather has had alzheimers for about 3 years and he has been taking Anatabloc for about 6 months. He has gone from a man who stares at the wall to a man who remembers everything from flying over the DMZ in the Korean war to my dad's high school graduation 40 years ago. I do not need to see any study. But the results will no doubt help the stock price.
    3 Oct 2012, 04:05 PM Reply Like
  • The_Hammer
    , contributor
    Comments (5114) | Send Message
    ST I am not sure exactlY what the purpose of the article is, but the USA has become when big pick pocket.


    2 Sep 2012, 09:53 PM Reply Like
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.